Editorial

iMedPub Journals
www.imedpub.com

Biomarkers Journal
ISSN 2472-1646

2021
Vol.7 No.11:e108

A Note on Inflammatory Biomarkers of Coronary Heart Disease

Lin Oliver*

Department of Population Health Sciences, School of Public Health, Atlanta, USA

***Corresponding author:** Lin Oliver, Department of Population Health Sciences, School of Public Health, Atlanta, USA, E-mail: oliverlin@gmail.com

Received date: November 3, 2021; **Accepted date:** November 17, 2021; **Published date:** November 24, 2021

Citation: Oliver L (2021) A Note on Inflammatory Biomarkers of Coronary Heart Disease. Biomark J. Vol. 7 No. 11:e108 .

Description

Coronary Heart Disease (CHD) is the main cause of mortality worldwide. The development of arterial plaques, which are mostly made up of lipids, calcium, and inflammatory cells, is a characteristic of CHD. The lumen of coronary arteries is decreased by these plaques, resulting in permanent angina. The rupture of these plaques induces the production of thrombus, which causes myocardial infarction and mortality due to the stoppage of blood flow. Obesity, diabetes, and hypertension are all risk factors for coronary heart disease. Blood cholesterol, triglycerides, and lipoproteins levels are used to make the diagnosis. Because inflammation plays a role in the development of CHD, inflammatory biomarkers such as interleukin-6, C-reactive protein, complement, and myeloperoxidase are used to determine the severity and prognosis of the disease.

CHD is more frequent in men than in women, and it is marked by angina, heart failure, and irregular heartbeats. Myocardial infarction, the largest cause of mortality in developed countries, can be caused by CHD. CHD may affect anybody at any age, but it becomes substantially more frequent as people become older, with the incidence increasing every decade. Coronary artery atherosclerosis is the fundamental cause of CHD. High blood pressure, obesity, diabetes mellitus, elevated blood cholesterol, smoking, lack of exercise; poor nutrition, excessive alcohol use, and depression are all risk factors for CHD. The level of blood cholesterol, triglycerides, and lipoproteins determines the diagnosis.

CHD is characterised by plaques that form as a result of the build up of fatty deposits, inflammatory cells, and calcification, causing artery rigidity. Gradual constriction of the lumen causes ischemia, which can cause ventricular arrhythmias, and closing the lumen causes ventricular fibrillation, which can lead to infarction.

C-Reactive Protein (CRP) is the most intensively studied inflammatory biomarker in CAD. This inflammatory biomarker possesses numerous qualities that make it very appealing. It is an acute phase protein that has been demonstrated to be a marker of systemic inflammation, with levels increasing in response to injury, infection, and other inflammatory stimuli. Hepatic production is directly connected to IL-6 activation, and unlike other acute phase reactants, its levels remain stable in the absence of additional stimuli for long periods of time.

However, CRP is not only a potent inflammatory marker; increasing results show that CRP may also play a direct role in the inflammatory process of atherogenesis. They also proposed that CRP plays a significant role in plaque vulnerability and the pathophysiology of unstable angina, as well as restenosis following coronary intervention. Similarly , the reseachers of that CRP is created at the region of the dangerous plaque by the observing a CRP gradient in coronary artery blood samples taken immediately distal and proximal to the culprit lesions.

In comparison to many other inflammatory biomarkers, high sensitivity CRP assessment methods are reliable, accessed directly, and sensitive, providing a basic clinical tool for the thorough assessment of systemic inflammation.